ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 197448" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.globenewswire.com/fr/news-release/2021/03/11/2191255/0/en/Acerus-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html[/URL]</p><p></p><div style="text-align: justify; max-width: %s"><strong>TORONTO, March 11, 2021 </strong>(GLOBE NEWSWIRE) --<em> Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”).</em></div> </p><div style="text-align: justify; max-width: %s"><strong>Recent Highlights</strong></div> </p><ul> <li data-xf-list-type="ul"><strong><em>Significant growth in US NATESTO® total prescriptions during the fourth quarter of 2020 – driven by the specialist (urologist and endocrinologist) segment</em></strong></li> <li data-xf-list-type="ul"><strong><em>Rights offering completed in November 2020, strengthening the balance sheet</em></strong></li> <li data-xf-list-type="ul"><strong><em><u>Shipments of NATESTO® to South Korea and Taiwan resumed in the fourth quarter</u></em></strong></li> <li data-xf-list-type="ul"><strong><em>The Company entered into an agreement with Torreya Partners LLC to identify strategic options for product acquisition and growth capital</em></strong></li> <li data-xf-list-type="ul"><em><strong><u>NATESTO® expected to be available in Canada by mid-2021</u></strong></em></li> </ul><p></p><div style="text-align: justify; max-width: %s"><em>“Fiscal 2020 was clearly a year of both challenge and opportunity for Acerus, putting us on solid footing for 2021 and beyond,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “While the global pandemic negatively impacted our ability to conduct business in North America and elsewhere, we laid the groundwork – even under such circumstances – for improved growth and bottom-line results going forward. I’m particularly pleased with the success of our NATESTO® rollout in the United States, where we saw prescription growth of 23% in the fourth quarter versus the third, and where we are encouraged by ongoing momentum thus far in the new year.</em></div> </p><div style="text-align: justify; max-width: %s"><em>“With COVID-19 restrictions slowly subsiding around the globe, we feel even more optimistic about the quarters to come. We continue to execute our strategy to bolster our presence in the US, return to the Canadian market, and expand our product offerings. Given improving demand dynamics and strengthened economic outlook, we believe Acerus is well-positioned for higher returns in 2021.”</em></div> </p><p></p><p></p><p></p><div style="text-align: justify; max-width: %s"><strong>NATESTO</strong>®</div> </p><div style="text-align: justify; max-width: %s"><em>The Company continues to execute its strategy of focusing on the US market for NATESTO®. Acerus, in conjunction with its US commercial provider Syneos Health Inc. (“Syneos”), has deployed a team of 32 personnel based in the United States, who conduct a substantial majority of the Corporation’s commercial operations in the United States. Total fourth-quarter 2020 prescription growth in the specialty physician segment (urology, endocrinology) was significant, up approximately 23% sequentially over the third quarter of 2020 and the Company is confident that this momentum – even in the face of COVID-19 restrictions limiting in-person physician visits, positions the Company for stronger top-line growth in 2021.</em></div> </p><div style="text-align: justify; max-width: %s"><strong><em>The Company remains optimistic about a return of NATESTO® to the Canadian market in the first half of 2021. <u>Manufacturing is ongoing on a new batch of NATESTO®</u> for this market in anticipation of the return to the Canadian market.</em></strong></div> </p><div style="text-align: justify; max-width: %s"><strong><em>Shipments to South Korea and Taiwan resumed in the fourth quarter of 2020, and further shipments are expected in the first quarter of 2021</em></strong></div></blockquote><p></p>
[QUOTE="madman, post: 197448, member: 13851"] [URL unfurl="true"]https://www.globenewswire.com/fr/news-release/2021/03/11/2191255/0/en/Acerus-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html[/URL] [JUSTIFY='%s'][B]TORONTO, March 11, 2021 [/B](GLOBE NEWSWIRE) --[I] Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”).[/I][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][B]Recent Highlights[/B][/JUSTIFY] [LIST] [*][B][I]Significant growth in US NATESTO® total prescriptions during the fourth quarter of 2020 – driven by the specialist (urologist and endocrinologist) segment[/I][/B] [*][B][I]Rights offering completed in November 2020, strengthening the balance sheet[/I][/B] [*][B][I][U]Shipments of NATESTO® to South Korea and Taiwan resumed in the fourth quarter[/U][/I][/B] [*][B][I]The Company entered into an agreement with Torreya Partners LLC to identify strategic options for product acquisition and growth capital[/I][/B] [*][I][B][U]NATESTO® expected to be available in Canada by mid-2021[/U][/B][/I] [/LIST] [B][U][I][/I][/U][/B] [JUSTIFY='%s'][I]“Fiscal 2020 was clearly a year of both challenge and opportunity for Acerus, putting us on solid footing for 2021 and beyond,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “While the global pandemic negatively impacted our ability to conduct business in North America and elsewhere, we laid the groundwork – even under such circumstances – for improved growth and bottom-line results going forward. I’m particularly pleased with the success of our NATESTO® rollout in the United States, where we saw prescription growth of 23% in the fourth quarter versus the third, and where we are encouraged by ongoing momentum thus far in the new year.[/I][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][I]“With COVID-19 restrictions slowly subsiding around the globe, we feel even more optimistic about the quarters to come. We continue to execute our strategy to bolster our presence in the US, return to the Canadian market, and expand our product offerings. Given improving demand dynamics and strengthened economic outlook, we believe Acerus is well-positioned for higher returns in 2021.”[/I][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][B]NATESTO[/B]®[/JUSTIFY] [JUSTIFY='%s'][I]The Company continues to execute its strategy of focusing on the US market for NATESTO®. Acerus, in conjunction with its US commercial provider Syneos Health Inc. (“Syneos”), has deployed a team of 32 personnel based in the United States, who conduct a substantial majority of the Corporation’s commercial operations in the United States. Total fourth-quarter 2020 prescription growth in the specialty physician segment (urology, endocrinology) was significant, up approximately 23% sequentially over the third quarter of 2020 and the Company is confident that this momentum – even in the face of COVID-19 restrictions limiting in-person physician visits, positions the Company for stronger top-line growth in 2021.[/I][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][B][I]The Company remains optimistic about a return of NATESTO® to the Canadian market in the first half of 2021. [U]Manufacturing is ongoing on a new batch of NATESTO®[/U] for this market in anticipation of the return to the Canadian market.[/I][/B][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [JUSTIFY='%s'][B][I]Shipments to South Korea and Taiwan resumed in the fourth quarter of 2020, and further shipments are expected in the first quarter of 2021[/I][/B][/JUSTIFY] [JUSTIFY='%s'][/JUSTIFY] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TEMPORARY UNAVAILABILITY OF NATESTO® IN CANADA AND SOUTH KOREA
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top